Physician profile
Shane G Lanys
NPI 1467412759
$5,414.22
in general payments reported to CMS, 2019-2025
33 companies · $214 in 2025
The $214 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $501 · 2021: $341 · 2022: $1,136 · 2023: $1,356 · 2024: $1,096 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,666.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $908.28 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $731.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $713.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $474.05 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.59 | 2019-2025 | Jardiance, Tradjenta |
| Amarin Pharma, INC. | $336.06 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $272.25 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $211.65 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $194.40 | 2024-2025 | Zenpep |
| Amgen INC. | $181.63 | 2019-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $146.74 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $105.90 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $98.70 | 2020-2023 | Verquvo, Steglatro, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.43 | 2019-2023 | Cycloset |
| Abbott Laboratories | $84.24 | 2020-2023 | Freestyle Libre 3 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $80.34 | 2021-2022 | |
| Astellas Pharma US INC | $47.30 | 2021-2024 | Veozah |
| Esperion Therapeutics, INC. | $35.99 | 2021 | |
| Pfizer INC. | $33.38 | 2023 | |
| Allergan, INC. | $32.67 | 2019-2020 | |
| Abbvie INC. | $30.53 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $30.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $24.82 | 2019 | |
| Teleflex LLC | $21.38 | 2023 | Urolift |
| Medtronic, INC. | $20.27 | 2024 | Intellis Adaptivestim |
| Eisai INC. | $19.83 | 2024 | |
| Redhill Biopharma INC. | $18.78 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.68 | 2022 | |
| Dexcom, INC. | $14.40 | 2021 | |
| Ibsa Pharma INC. | $13.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2019 | |
| Shield Therapeutics INC | $12.99 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $12.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Lanys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.